Your trusted source for investing success
The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.
Nabriva Therapeutics plc saw its stock get a major boost on Monday morning after the company announced top-line results from their trial of a pneumonia drug.
Oncolytics Biotech shared the results from a positive End-of-Phase 2 meeting with the FDA for REOLYSIN in combination with paclitaxel.
Aeolus Pharmaceuticals announced it met its primary endpoint for a phase 1 ascending dose escalation study.
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer.
“The opening of this
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021. Here are 10 top stem cell companies on the NASDAQ.
The medical device industry is robust and diverse. Here are four small medical device companies that investors should watch.
Major players in the pharmaceutical industry include Johnson & Johnson, Novartis, Roche, Pfizer and Merck.
EDAP TMS announced the submission of a new 510(k) application for its Focal One device, including an updated clinical section for FDA review.
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the initiation of a Phase 2 clinical trial for its lead agent VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The biomarker-driven clinical trial will explore safety and efficacy of chemoradiation with VAL-083 as
By Shelly Kumar
RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders, including sleep apnea, opioid-induced respiratory depression, and respiratory insufficiency due to spinal cord injury, announces that the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, James
What if the “one-size-fits-all” approach to medicine isn’t the right way treat medical conditions? Could a personalized medicine approach provide better treatment?
Cipher Pharmaceuticals issued a response to the warning letter from the FDA regarding their pain reliever ConZip.
Attacks on medical devices is a growing problem, while the budget on medical device security is expected to reach $101 billion by 2018.
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that Jeffrey Bacha, president & CEO of the Company, will be presenting at the 19th Annual Rodman & Renshaw Global Investment Conference being held September 10-12, 2017, at the Lotte New York Palace Hotel in New York
Aeglea BioTherapeutics dosed two adults in the repeat dose part of its Phase 1/2 clinical trial of AEB1102 for the treatment of patients with Arginase 1 Deficiency.
Oncology investing can certainly be intimidating. Here, the Investing News Network looks at companies in the space and other ways to invest.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
